Free Trial
NASDAQ:MOLN

Molecular Partners Q1 2025 Earnings Report

Molecular Partners logo
$3.84 -0.01 (-0.26%)
As of 05/16/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Molecular Partners EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.39
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

Molecular Partners Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Molecular Partners Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 19, 2025
Conference Call Time
3:00AM ET

Conference Call Resources

Molecular Partners Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Molecular Partners Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Molecular Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Molecular Partners and other key companies, straight to your email.

About Molecular Partners

Molecular Partners (NASDAQ:MOLN), a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

View Molecular Partners Profile

More Earnings Resources from MarketBeat